19 / 38
TMB in prospective trial
–
Patients with advanced NSCLC (N = 580)
–
Treatment-naïve
–
PD-L1 unselected
Alectinib 600 BID
Primary objective: ORR per RECIST v1.1
Secondary objectives: safety, OS, PFS, DOR
Cohort A: ALK +
Cohort B: RET+
Cohort C: bTMB
Alectinib 900-1200 BID
Atezolizumab
1200 Q3W
Platinum
CT Q3W
Primary objective: PFS
Secondary objectives: RR, safety,
OS, DOR
BFAST trial phase II/III
Press release – 5
th
Feb 2018
Ph. III CheckMate 227: Nivo + Ipi
vs.
CT
Positive for PFS in TMB High (> 10 Mut/Mb)
Regardless of PD-L1 expression